Biobank Healthy Volunteer Program

Summary

Currently the Biobank of the Molecular Classification of Kidney Disease (BMCKD) is a fully operational biobank operating in both clinical and research capacities. The BMCKD collects, processes, stores, and transfers biospecimens from patients who have evidence or diagnoses of kidney disease.

As the BMCKD continues to expand the size of its repository, it becomes increasingly important to collect biospecimens from healthy volunteers in order to provide healthy control groups for comparative analysis to support future research projects in precise diagnostic testing and genetic studies. Participants provide a ONE TIME donation of blood and urine which will be de-identified.



Eligibility

Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Accepts healthy participants: Yes

Inclusion criteria:

Participants must be:
a) > 18 years of age
b) Healthy [absence of serious co-morbidities including cardiovascular disease, diabetes, obesity (BMI > 30), hypertension, systemic or infectious disease]
c) Normal kidney function (eGFR > 60) or no knowledge of kidney dysfunction
d) Normal urinalysis

Exclusion criteria:

a. Prior immunosuppression eg. steroids
b. Pregnancy
c. Not healthy [presence of serious co-morbidities including cardiovascular disease, diabetes, obesity (BMI > 30), hypertension, systemic or infectious disease]
d. Abnormal kidney function (eGFR < 60) or knowledge of kidney problems
e. Proteinuria > 200mg/d or albumin creatinine ratio > 3.4 mg/mml or dipstick positive for protein
f. Unable to fully disclose smoking status, prior medical complications, medications

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

If you would like to learn more, please contact Graciela Andonegui at andonegu@ucalgary.ca

Principal investigator:

Daniel Abraham Muruve

Clinical trial:

No

REB-ID:

REB16-0622